Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia
- 1 October 1985
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 61 (2), 261-265
- https://doi.org/10.1111/j.1365-2141.1985.tb02824.x
Abstract
Summary. Anthracyclines given by continuous infusion, as opposed to bolus administration, are associated with a reduced incidence of cardiac and gastrointestinal toxicity. Our study was developed to test the antileukaemic effect of anthracyclines given as a continuous infusion. Nineteen sequential patients admitted for treatment of acute nonlymphocytic leukaemia (ANLL) were managed with a regimen utilizing a 3 d continuous intravenous infusion of daunomycin (DNM), and the complete response rate was similar to this institution's past experience with antileukaemic regimens employing 3 d bolus DNM. In our studies, infusion DNM was at least as myelotoxic and antileukaemic as bolus DNM; thus this method of administration should be explored further in remission-induction regimens for ANLL.This publication has 6 references indexed in Scilit:
- Continuous Infusion or Bolus Injection in Cancer ChemotherapyAnnals of Internal Medicine, 1983
- Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly ScheduleAnnals of Internal Medicine, 1983
- CLINICAL-EVALUATION OF LONG-TERM, CONTINUOUS-INFUSION DOXORUBICIN1983
- Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancerCancer, 1982
- Treatment of acute nonlymphocytic leukemia: use of anthracycline- cytosine arabinoside induction therapy and comparison of two maintenance regimensBlood, 1979